FRIDAY, June 9, 2017 -- A host of new drugs that appear to prevent migraine headaches are in the final stages of testing and approval in the United States. Advertisement "What's really exciting about ...

Peter L. Salgo, MD: Let’s go a bit more off the reservation. We’ve got the gammaCore neurostimulation device. What is that? Peter Goadsby, MD, PhD: GammaCore is a noninvasive vagus nerve stimulator.

Competing teams of researchers are closing in on a new class of drugs that can prevent chronic migraines by interrupting the chain of events thought to create the headaches. The drugs target a ...

Peter L. Salgo, MD: There are some newly approved classes of agents out there—human monoclonal antibodies, MAB treatments, that block the calcitonin gene-related peptide, CGRP. What is their mechanism ...

image: Dr. Peter Goadsby, professor of neurology at the David Geffen School of Medicine at UCLA, has been chosen as one of four recipients of the Brain Prize 2021. The prize honors scientists who have ...

SAN FRANCISCO, Dec. 14, 2022 /PRNewswire/ -- Vial, a global tech-enabled CRO providing next-generation clinical trial management services, welcomes Dr. Peter Goadsby as a new Central Nervous System ...